Skip to Content

AstraZeneca PLC ADR AZN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Coronavirus to Create $39 Billion Vaccine Market and $10 Billion Treatment Market in 2021

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

Following a year with more than 83 million reported cases and 1.8 million reported deaths globally due to COVID-19, 2021 begins as two newly authorized vaccines are distributed to high-priority populations in the United States and Europe. These mRNA vaccines from Pfizer/BioNTech and Moderna have set a high bar for efficacy and safety, and they appear poised to ramp up supply and dominate the U.S. market throughout the first half of the year, supporting a foundation for herd immunity in the U.S. by midyear. With additional support from Johnson & Johnson, Novavax, AstraZeneca, and Chinese and Russian vaccine programs, global herd immunity looks achievable by 2023.

Read Full Analysis

Company Profile

Business Description

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Contact
1 Francis Crick Avenue, Cambridge Biomedical Campus
Cambridge, CB2 0AA, United Kingdom
T +44 2037495000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 70,600

Related